TY - JOUR
T1 - SARS-CoV-2 spike IgG titres up to 137days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
AU - Patalon, Tal
AU - Moshe, Shay Ben
AU - Peretz, Asaf
AU - Neuberger, Ami
AU - Schreiber, Licita
AU - Lazar, Rachel
AU - Supino-Rosin, Lia
AU - Perez, Galit
AU - Mizrahi-Reuveni, Miri
AU - Gazit, Sivan
N1 - Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2022/10/6
Y1 - 2022/10/6
N2 - Background: Data regarding the long-term protection afforded by vaccination for the SARS-CoV-2 infection are essential for allocation of scarce vaccination resources worldwide. Methods: We conducted a retrospective cohort study aimed at studying the kinetics of IgG antibodies against SARS-CoV-2 in COVID-19-naïve patients fully vaccinated with two doses of Comirnaty mRNA COVID-19 vaccine. Geometric mean concentrations (GMCs) of antibody levels were reported. Linear models were used to assess antibody levels after full vaccination and their decline over time. Results: The study included 4,740 patients and 5,719 serological tests. Unadjusted GMCs peaked 28–41days after the first dose at 10,174AU/mL (95%CI:9,211–11,237) and gradually decreased but remained well above the positivity cut-off. After adjusting for baseline characteristics and repeated measurements, the antibodies half-life time was 34.1days (95%CI:33.1–35.2), and females aged 16–39years with no comorbidities had antibody levels of 20,613AU/mL (95%CI:18,526–22,934) on day28 post-first-dose. Antibody levels were lower among males (0.736 of the level measured in females; 95% CI: 0.672–0.806), people aged 40–59 (0.729; 95% CI: 0.649–0.818) and ≥ 60 years (0.452; 95% CI: 0.398–0.513), and patients having haematological (0.241; 95% CI: 0.190–0.306) or solid malignancies (0.757; 95% CI: 0.650–0.881), chronic kidney disease with glomerular filtration rate (GFR) ≥ 30 (0.434; 95% CI: 0.354–0.532) or with GFR < 30 mL/min (0.176; 95% CI: 0.109–0.287), and immunosuppression (0.273; 95% CI: 0.235–0.317). Body mass index, cardiovascular disease, congestive heart failure, chronic obstructive pulmonary disease, diabetes and inflammatory bowel diseases were not associated with antibody levels. Conclusions: Vaccination with two doses resulted in persistently high levels of antibodies (≥ cut-off of 50 AU/mL) up to 137 days post-first-dose. Risk factors for lower antibody levels were identified.
AB - Background: Data regarding the long-term protection afforded by vaccination for the SARS-CoV-2 infection are essential for allocation of scarce vaccination resources worldwide. Methods: We conducted a retrospective cohort study aimed at studying the kinetics of IgG antibodies against SARS-CoV-2 in COVID-19-naïve patients fully vaccinated with two doses of Comirnaty mRNA COVID-19 vaccine. Geometric mean concentrations (GMCs) of antibody levels were reported. Linear models were used to assess antibody levels after full vaccination and their decline over time. Results: The study included 4,740 patients and 5,719 serological tests. Unadjusted GMCs peaked 28–41days after the first dose at 10,174AU/mL (95%CI:9,211–11,237) and gradually decreased but remained well above the positivity cut-off. After adjusting for baseline characteristics and repeated measurements, the antibodies half-life time was 34.1days (95%CI:33.1–35.2), and females aged 16–39years with no comorbidities had antibody levels of 20,613AU/mL (95%CI:18,526–22,934) on day28 post-first-dose. Antibody levels were lower among males (0.736 of the level measured in females; 95% CI: 0.672–0.806), people aged 40–59 (0.729; 95% CI: 0.649–0.818) and ≥ 60 years (0.452; 95% CI: 0.398–0.513), and patients having haematological (0.241; 95% CI: 0.190–0.306) or solid malignancies (0.757; 95% CI: 0.650–0.881), chronic kidney disease with glomerular filtration rate (GFR) ≥ 30 (0.434; 95% CI: 0.354–0.532) or with GFR < 30 mL/min (0.176; 95% CI: 0.109–0.287), and immunosuppression (0.273; 95% CI: 0.235–0.317). Body mass index, cardiovascular disease, congestive heart failure, chronic obstructive pulmonary disease, diabetes and inflammatory bowel diseases were not associated with antibody levels. Conclusions: Vaccination with two doses resulted in persistently high levels of antibodies (≥ cut-off of 50 AU/mL) up to 137 days post-first-dose. Risk factors for lower antibody levels were identified.
UR - http://www.scopus.com/inward/record.url?scp=85139278380&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2022.27.40.2100703
DO - 10.2807/1560-7917.ES.2022.27.40.2100703
M3 - Article
C2 - 36205168
AN - SCOPUS:85139278380
SN - 1025-496X
VL - 27
JO - Eurosurveillance
JF - Eurosurveillance
IS - 40
M1 - 2100703
ER -
